

State of Oklahoma SoonerCare

Mvasi® (Bevacizumab-awwb) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Informati	ion
□Physician billing (HCPCS	code:) □Pharma	cy billing (NDC:)
Dose: Re	egimen:S	tart Date (or date of next dose):
	Billing Provider Info	ormation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Inform	ation
Prescriber NPI:	Prescriber Name.	:
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
maly), Avastin [®] (bevae	cizumab), Vegzelma [®] (bevacizum	ember cannot use Alymsys [®] (bevacizumab- ab-adcd), or Zirabev [®] (bevacizumab-bvzr):
3. Has the member experience of yes, please specify adverse	dence of progressive disease while ced any adverse drug reactions rel	e on Mvasi [®] therapy? Yes No lated to Mvasi [®] therapy? Yes No
I certify that the indicated treat	ment is medically necessary and all this form in full will result in processing	Il information is true and correct to the best of my

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 166 8/21/2023